Executive summary
US Patent 8,093,423 claims use of ferric citrate with a tightly defined intrinsic dissolution rate (1.88 to 4.0 mg/cm²/min) to treat or prevent calcium-phosphate mineralization outcomes in dialysis or ESRD populations. Claim scope centers on method-of-treatment endpoints (mortality reduction, reduced [Ca]×[P], reduced serum phosphate/calcium, reversal of soft-tissue calcification, and kidney-stone dissolution assistance) plus layered limitations covering oral administration, dosing bands (2 to 30 g/day; preferred 2, 4, 6 g/day; specific 1/6/8 g/day), meal timing, dosage forms (broad catch-all), and comparative tolerability versus “chemical-grade ferric citrate.” The patent landscape around these claims typically concentrates on (i) ferric citrate composition/intrinsic dissolution rate variants and (ii) dialysis-related mineral disorder endpoints, with attack risk most concentrated in obviousness and written-description/enablement around the dissolution-rate window and the asserted clinical outcomes.
US Patent 8,093,423 Ferric Citrate Intrinsic Dissolution Rate 1.88–4.0 mg/cm²/min Claims Scope and Patent Landscape
What exactly do the claims of US 8,093,423 cover for ferric citrate in dialysis patients?
Core claim theme: the claims are method-of-use claims that require a particular physicochemical parameter of the active ferric citrate, then tie administration of that material to specific clinical or surrogate outcomes relevant to chronic kidney disease-mineral and bone disorder (CKD-MBD).
Claim 1: “decreasing mortality rate” in dialysis with dissolution-rate specified ferric citrate
- Population: “a dialysis patient” (broad; depends on later dependent claims for ESRD and dialysis modality).
- Active requirement: ferric citrate with intrinsic dissolution rate of 1.88 to 4.0 mg/cm²/min.
- Endpoint: “decrease mortality rate.”
Practical scope effect: the mortality endpoint is a high bar for proof in infringement, but the claim is still broad in method form: infringement can be argued without requiring the patient to be in a trial, as long as the method is practiced and yields the endpoint in the claimed manner.
Claims 2-4: mineralization and calcium/phosphate biochemistry endpoints
- Claim 2: inhibit calcium phosphate deposition.
- Claim 3: decrease calcium-phosphorus product ([Ca]×[P]).
- Claim 4: decrease serum calcium levels.
- Shared requirement across claims 2-4: ferric citrate with intrinsic dissolution rate 1.88–4.0 mg/cm²/min.
Claim strategy: these claims shift from mortality (hardest clinically) to mechanistic/biochemical mineralization metrics commonly tracked in CKD-MBD management. In many disputes, these endpoints are easier to evidence than mortality.
Claims 5-7: calcification reversal and urinary calculus support
- Claim 5: reverse calcification of soft tissue.
- Claim 6: aid dissolving a kidney stone.
- Claim 7: reduce serum phosphate levels.
- Shared requirement: dissolution-rate window on ferric citrate.
Scope effect: “reverse calcification” and “aid dissolving a kidney stone” expand the claim footprint beyond CKD-MBD mineral measures toward imaging-confirmed or clinical resolution outcomes.
Claims 8-10: oral use, meal timing, and an unusually broad dosage-form portfolio
- Claim 8: oral administration.
- Claim 9: administered with a meal.
- Claim 10: dosage forms include tablet, powder, suspension, emulsion, capsule, lozenge, granule, troche, pill, liquid, spirit, syrup.
Interpretation impact: the dosage-form clause is a broad “either-or” catch-all, reducing design-around value based purely on changing presentation.
Claims 11-12 and 20-22: dosing bands and specific daily dose integers
- General dose band (claims 11, 26): ~2 g/day to ~30 g/day.
- Preferred selected doses (claims 12, 27): 2, 4, 6 g/day.
- Specific dose dependent claims (claims 20, 21, 22; mirrored in later dependent sets): 1 g/day, 6 g/day, 8 g/day.
Scope effect: competitors must avoid not only the dissolution-rate window but also these dose ranges or carve out entirely different regimens. Because claims include both broad ranges and specific enumerated values, even partial overlaps create infringement risk.
Claims 13-14 and mirrored sets: tolerability comparison vs “chemical-grade ferric citrate”
- Claim 13: fewer side effects than “chemical-grade ferric citrate.”
- Claim 14: side effects selected from diarrhea, loose stool, constipation, bloating, nausea.
Scope effect: this adds a comparative-performance limitation. In infringement, it can be used both ways:
- It can strengthen a patentee’s narrative on differentiation (and help rebut obviousness).
- It can create an evidentiary requirement for a challenger to show comparative tolerability is not met.
Claims 15-17 and mirrored sets: ESRD and dialysis modalities
- Claim 15: subject has end stage renal disease (ESRD).
- Claim 16: subject is on dialysis.
- Claim 17: dialysis is hemodialysis or peritoneal dialysis.
Scope effect: these dependent claims lock population/dialysis modality. An accused method performed in non-dialysis CKD (or transplant, pre-dialysis CKD) can avoid these dependent claims while still potentially implicating independent claims that do not require ESRD.
How narrow is the dissolution-rate limitation (1.88 to 4.0 mg/cm²/min) and what does it do to infringement?
Dissolution-rate is the core differentiator across claims 1-7: it is a material limitation on the ferric citrate administered. That means:
- Infringement arguments will focus on whether the accused product’s ferric citrate has an intrinsic dissolution rate within the specified range.
- Design-arounds can target manufacturing/process changes intended to shift intrinsic dissolution outside 1.88–4.0 mg/cm²/min, but those efforts face risk if the dissolution parameter is robust or hard to tune without losing clinical utility.
Claim-construct risk for the patentee (validity lever for challengers):
- If the patent record does not support the dissolution-rate window across relevant batches/conditions, challengers may press for lack of written description/enablement.
- If ferric citrate intrinsic dissolution rate is not consistently measurable or varies with test conditions, disputes can arise on measurement methodology and equivalence.
What limitations relate to administration route, timing, and formulation in US 8,093,423?
The independent method endpoints are paired with broad dependent coverage of how the drug is given.
Route and timing
- Oral administration (claims 8, 23, 38, 53, 68).
- Administered with a meal (claims 9, 24, 39, 54, 69).
Dosage forms
The claim 10 list is very broad: tablets, powders, suspensions, emulsions, capsules, lozenges, granules, troches, pills, liquids, spirits, and syrups.
Practical scope note: many formulation substitutes still remain “oral” and “listed forms,” so design-around value via presentation is limited. A more reliable strategy, where feasible, is shifting out of the dissolution-rate window or avoiding the claimed dose/time regimen.
What clinical and mechanistic outcomes are claimed, and how do they map to CKD-MBD mineral management?
US 8,093,423 claims a spectrum of endpoints that fall into two buckets.
Mineral control biomarkers and mineralization
- Inhibit calcium phosphate deposition (claim 2).
- Decrease calcium-phosphorus product [Ca]×[P] (claim 3).
- Decrease serum calcium (claim 4).
- Reduce serum phosphate (claim 7).
- Reverse calcification of soft tissue (claim 5).
Harder clinical endpoints
- Decrease mortality rate in dialysis patients (claim 1).
- Aid in dissolving a kidney stone (claim 6).
Scope effect: The presence of both biomarker and mortality/stone endpoints increases the ability to assert infringement across multiple clinical evidence types. For a challenger, that expands the set of studies that can be used to argue that the claimed method is obvious or not enabled, but also can make it harder to negate infringement across all asserted endpoints.
When does US 8,093,423 lose exclusivity for generic or biosimilar competition?
No exclusivity/effective loss timeline can be calculated from the claim text provided alone. Exclusivity end date depends on the patent’s issuance details, filing date, term adjustments, and any terminal disclaimers, none of which are included in the prompt.
What is the Orange Book status of ferric citrate products potentially implicated by US 8,093,423?
No Orange Book listing or status can be produced from the prompt. The claim text does not supply FDA product identifiers (application numbers, listed drug names, or Orange Book entries).
How strong is the patent estate around US 8,093,423, and what claims are most attackable?
Even without the full specification, the claim structure identifies likely validity pressure points that are common in ferric citrate intrinsic-parameter patents.
Most likely validity attack vectors
- Intrinsic dissolution-rate support: Challengers typically target whether the patent specification enables ferric citrate with intrinsic dissolution rates across 1.88–4.0 mg/cm²/min and whether the parameter is tied to reproducible manufacturing controls.
- Obviousness from known ferric citrate: If ferric citrate compositions and their CKD-MBD utility were known, the key question becomes whether the dissolution-rate window is an obvious selection or materially distinguishes prior art.
- Mortality endpoint enablement: Claim 1’s mortality framing can be attacked if the record does not teach how to achieve mortality reduction or if the data set is too limited for broad dialysis populations.
- “Chemical-grade” comparative tolerability: The comparative side-effect limitation may be challenged for indefiniteness or lack of clear testing criteria to define “chemical-grade ferric citrate” and to ensure consistent comparative results.
Most likely infringement pressure points
- Dissolution-rate measurement: Claim construction can hinge on measurement protocol and whether the accused product’s intrinsic dissolution rate meets the range.
- Dose and regimen overlap: Broad dose bands plus enumerated doses (1, 6, 8 g/day; 2, 4, 6 g/day) reduce “range” carve-outs.
- Population fit: Dependent claims specify ESRD and dialysis types; independent claims use “dialysis patient” and can be argued broadly depending on claim construction.
What generic entry risks exist for ferric citrate methods that target CKD-MBD endpoints?
Risk is highest if a generic or follow-on product:
- matches ferric citrate but keeps manufacturing conditions that fall within the intrinsic dissolution-rate window, and
- uses labeled or standard-of-care dosing that overlaps 2–30 g/day or enumerated doses (2, 4, 6, 1, 6, 8 g/day in dependencies), and
- is prescribed with meal timing (where dependent claims are asserted), and
- is used in dialysis/ESRD settings to treat phosphate/calcium/mineralization.
Risk is lower if the competitor:
- shifts dissolution rate outside 1.88–4.0 mg/cm²/min,
- uses materially different dosing regimens outside claimed ranges, or
- avoids the claimed dialysis population context.
What patent litigation factors typically matter for method-of-use patents like US 8,093,423?
For method-of-use claims, disputes tend to center on:
- Claim construction of “intrinsic dissolution rate” and how it is measured.
- Product attribute proof (tests on accused product lots, manufacturing records, specs, batch variation).
- Induced direct infringement theories (if the asserted method is practiced by clinicians using the accused product).
- Comparative claims (side-effect fewer than “chemical-grade” and definitions around that comparator).
Because the claim set is dense and layered (dissolution rate plus numerous dependent conditions), a challenger often faces an “all elements” problem if infringement requires proving the dissolution-rate limitation plus the endpoint plus the administrative parameters.
Key Takeaways
- US 8,093,423 is built around a material limitation: ferric citrate with intrinsic dissolution rate 1.88–4.0 mg/cm²/min, then multiple dialysis-relevant mineral/calcification outcomes.
- The claim set ranges from mortality reduction (claim 1) to biomarkers and mineralization metrics ([Ca]×[P], serum calcium/phosphate, calcium phosphate deposition) and expands to soft-tissue calcification reversal and kidney stone dissolution support.
- Dependent claims broaden enforcement across oral administration, with-meal dosing, broad dosage forms, and overlapping dosing bands including enumerated daily doses.
- The most sensitive technical and legal fulcrum is the ability to measure and match the dissolution-rate window in accused ferric citrate products, followed by evidence of claimed clinical endpoints and comparative tolerability elements.
FAQs
- Can a ferric citrate generic avoid infringement by changing tablet strength while staying within the same dissolution-rate window?
- How do “intrinsic dissolution rate” limitations typically get proven in US method-of-use patent cases for drug products?
- Does claiming “dialysis patient” limit infringement only to hemodialysis, or can peritoneal dialysis also fall within the independent claim scope?
- What evidentiary role does the “fewer side effects than chemical-grade ferric citrate” limitation usually play in litigation?
- If a product’s dosing differs from 2–30 g/day but still targets phosphate reduction in dialysis, which claim elements most often break infringement?
References
- (No citable sources were provided in the prompt beyond the claim text; no external databases were supplied.)
